iA Global Asset Management Inc. Raises Stock Position in DexCom, Inc. (NASDAQ:DXCM)

iA Global Asset Management Inc. boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 81,003 shares of the medical device company’s stock after buying an additional 1,694 shares during the period. iA Global Asset Management Inc.’s holdings in DexCom were worth $11,235,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after buying an additional 136,282 shares in the last quarter. Capital Research Global Investors grew its position in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its position in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares in the last quarter. Capital World Investors grew its position in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its position in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research analyst reports. Morgan Stanley cut their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus cut their price objective on DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, July 26th. UBS Group lowered their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, Robert W. Baird downgraded shares of DexCom from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $161.00 to $80.00 in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $111.50.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,483 shares of company stock worth $401,450. Company insiders own 0.30% of the company’s stock.

DexCom Trading Up 3.7 %

NASDAQ DXCM traded up $2.50 during trading on Thursday, hitting $70.32. The stock had a trading volume of 11,190,289 shares, compared to its average volume of 3,571,464. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The stock has a market capitalization of $28.18 billion, a price-to-earnings ratio of 43.76, a P/E/G ratio of 2.16 and a beta of 1.16. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock has a 50 day simple moving average of $111.54 and a 200 day simple moving average of $122.55.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.